Daniel Wang

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 9

Top Topics

Metastatic Colorectal Cancer

Palliative Care

Drug Administration

Cross Sectional

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Christina J Waldron, Satoko Ito, Daniel Wang, Cecily Allen, Giri Viswanathan, Robert D Bona, Adam Cuker, George Goshua
Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States. Blood 143 (22) (2024)
Christina J Waldron, Satoko Ito, Daniel Wang, Cecily Allen, Giri Viswanathan, Robert D Bona, Adam Cuker, George Goshua
Cost-effectiveness of prophylaxis with recombinant versus plasma-derived VWF in severe von Willebrand disease in the US. Blood (2024)
Daniel Wang, Satoko Ito, Christina J Waldron, Ayesha Butt, Ellen Zhang, Harlan M Krumholz, David J Kuter, George Goshua
Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood advances 8 (11) (2024)
Daniel Wang, Satoko Ito, Christina J Waldron, Ayesha Butt, Ellen Zhang, Harlan M Krumholz, David J Kuter, George Goshua
Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood advances 8 (11) (2024)
Daniel Wang, Satoko Ito, Christina J Waldron, Ayesha Butt, Ellen Zhang, Harlan M Krumholz, David J Kuter, George Goshua
Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood advances 8 (11) (2024)
Daniel Wang, Satoko Ito, Christina J Waldron, Ayesha Butt, Ellen Zhang, Harlan M Krumholz, David J Kuter, George Goshua
Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood advances (2024)
Daniel Wang, Satoko Ito, Christina J Waldron, Ayesha Butt, Ellen Zhang, Harlan M Krumholz, David J Kuter, George Goshua
Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood advances 8 (11) (2024)
Daniel Wang, Satoko Ito, Christina J Waldron, Ayesha Butt, Ellen Zhang, Harlan M Krumholz, David J Kuter, George Goshua
Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood advances (2024)
Christina J Waldron, Satoko Ito, Daniel Wang, Cecily Allen, Giri Viswanathan, Robert D Bona, Adam Cuker, George Goshua
Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States. Blood 143 (22) (2024)